Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Stock Information for Sangamo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sangamo Therapeutics Inc.

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.